TY - JOUR
T1 - Renal transplantation in systemic lupus erythematosus
T2 - One center’s experience
AU - Roth, David
AU - Milgrom, Martin
AU - Esquenazi, Violet
AU - Strauss, Jose
AU - Zilleruelo, Gaston
AU - Miller, Joshua
PY - 1987/1/1
Y1 - 1987/1/1
N2 - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.
AB - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.
KW - End-stage renal disease
KW - Recurrent disease
KW - Renal transplantation
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=0023515316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023515316&partnerID=8YFLogxK
U2 - 10.1159/000167615
DO - 10.1159/000167615
M3 - Article
C2 - 3324763
AN - SCOPUS:0023515316
VL - 7
SP - 367
EP - 374
JO - American Journal of Nephrology
JF - American Journal of Nephrology
SN - 0250-8095
IS - 5
ER -